<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0185998.ref018">
 <label>18</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Coats</surname>
   <given-names>SJ</given-names>
  </name>, 
  <name>
   <surname>Garnier-Amblard</surname>
   <given-names>EC</given-names>
  </name>, 
  <name>
   <surname>Amblard</surname>
   <given-names>F</given-names>
  </name>, 
  <name>
   <surname>Ehteshami</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Amiralaei</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Zhang</surname>
   <given-names>H</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Chutes and ladders in hepatitis C nucleoside drug development</article-title>. 
  <source>Antiviral Res</source>. 
  <year>2014</year>;
  <volume>102</volume>:
  <fpage>119</fpage>â€“
  <lpage>47</lpage>. 
  <comment>doi: 
   <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.antiviral.2013.11.008" xmlns:xlink="http://www.w3.org/1999/xlink">10.1016/j.antiviral.2013.11.008</ext-link>
  </comment> .
  <?supplied-pmid 24275341?>
  <pub-id pub-id-type="pmid">24275341</pub-id>
 </mixed-citation>
</ref>
